akoya biosciences is developing a novel high-parameter tissue analysis platform, at an order of magnitude beyond what is currently possible. our codex (tm) (co-detection by indexing) system enables deep proteomic profiling...all on your existing microscope. if you are a scientist or software engineer interested in revolutionizing the science of imaging, then akoya is the place for you. contact is at info@akoyabio.com.
Company profile
Ticker
AKYA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
475586242
AKYA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
4 Mar 24
10-K
2023 FY
Annual report
4 Mar 24
8-K
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
4 Mar 24
8-K
Departure of Directors or Certain Officers
10 Jan 24
8-K
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
8 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
8 Nov 23
Transcripts
AKYA
Earnings call transcript
2023 Q3
8 Nov 23
AKYA
Earnings call transcript
2023 Q2
7 Aug 23
AKYA
Earnings call transcript
2023 Q1
8 May 23
AKYA
Earnings call transcript
2022 Q4
6 Mar 23
AKYA
Earnings call transcript
2022 Q3
8 Nov 22
AKYA
Earnings call transcript
2022 Q2
9 Aug 22
AKYA
Earnings call transcript
2022 Q1
8 May 22
AKYA
Earnings call transcript
2021 Q4
15 Mar 22
AKYA
Earnings call transcript
2021 Q3
9 Nov 21
AKYA
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
4
John Frederick Ek
2 Apr 24
4
Frederic Pla
25 Mar 24
4
Niro Ph.D Ramachandran
25 Mar 24
4
Brian McKelligon
25 Mar 24
4
Brian McKelligon
22 Mar 24
4/A
Brian McKelligon
22 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Brian McKelligon
14 Mar 24
4
ROBERT G SHEPLER
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 78.93 mm | 78.93 mm | 78.93 mm | 78.93 mm | 78.93 mm | 78.93 mm |
Cash burn (monthly) | 4.91 mm | (no burn) | 4.30 mm | 5.95 mm | 4.58 mm | 4.61 mm |
Cash used (since last report) | 33.87 mm | n/a | 29.67 mm | 41.03 mm | 31.63 mm | 31.81 mm |
Cash remaining | 45.05 mm | n/a | 49.25 mm | 37.89 mm | 47.29 mm | 47.11 mm |
Runway (months of cash) | 9.2 | n/a | 11.5 | 6.4 | 10.3 | 10.2 |
Institutional ownership, Q3 2023
74.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 65 |
Opened positions | 6 |
Closed positions | 17 |
Increased positions | 31 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 69.62 bn |
Total shares | 36.45 mm |
Total puts | 1.40 k |
Total calls | 32.40 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Telegraph Hill Partners III | 15.68 mm | $239.99 mm |
Blue Water Life Science Advisors | 4.70 mm | $21.84 bn |
PSC Capital Partners | 2.72 mm | $0.00 |
Yair Chaim Schindel | 2.50 mm | $13.60 mm |
Polar Capital | 1.58 mm | $7.35 bn |
BLK Blackrock | 1.45 mm | $6.72 bn |
Vanguard | 1.35 mm | $6.28 bn |
Kent Lake Capital | 746.52 k | $3.47 bn |
Board of Trustees of The Leland Stanford Junior University | 620.43 k | $2.89 bn |
Uniplan Investment Counsel | 554.56 k | $2.58 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | John Frederick Ek | Common Stock | Payment of exercise | Dispose F | No | No | 4.56 | 14,272 | 65.08 k | 180,728 |
23 Mar 24 | Frederic Pla | Common Stock | Payment of exercise | Dispose F | No | No | 4.79 | 2,006 | 9.61 k | 101,500 |
23 Mar 24 | Niro Ph.D Ramachandran | Common Stock | Payment of exercise | Dispose F | No | No | 4.79 | 2,006 | 9.61 k | 207,924 |
23 Mar 24 | Brian McKelligon | Common Stock | Payment of exercise | Dispose F | No | No | 4.79 | 7,135 | 34.18 k | 224,733 |
20 Mar 24 | Brian McKelligon | Common Stock | Sell | Dispose S | No | Yes | 4.9657 | 7,500 | 37.24 k | 231,868 |
20 Mar 24 | Brian McKelligon | Common Stock | Option exercise | Acquire M | No | No | 0.303 | 7,500 | 2.27 k | 239,368 |
20 Mar 24 | Brian McKelligon | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.303 | 7,500 | 2.27 k | 290,629 |
News
UBS Maintains Buy on Akoya Biosciences, Raises Price Target to $7.5
5 Mar 24
Canaccord Genuity Reiterates Buy on Akoya Biosciences, Maintains $10 Price Target
5 Mar 24
Akoya Biosciences Sees FY24 Revenue $114M-$118M Vs $117.38M Est.
4 Mar 24
Recap: Akoya Biosciences Q4 Earnings
4 Mar 24
Akoya Biosciences Q4 2023 GAAP EPS $(0.22) Beats $(0.28) Estimate, Sales $26.49M Beat $25.89M Estimate
4 Mar 24